| Title |
Etanercept for the treatment of rheumatoid arthritis
|
|---|---|
| Published in |
Cochrane database of systematic reviews, May 2013
|
| DOI | 10.1002/14651858.cd004525.pub2 |
| Pubmed ID | |
| Authors |
Anne Lethaby<sup>a</sup>, Maria Angeles Lopez‐Olivo<sup>a</sup>, Lara J Maxwell, Amanda Burls, Peter Tugwell, George A Wells |
| Abstract |
Etanercept is a soluble tumour necrosis factor alpha-receptor disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Spain | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 280 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | <1% |
| Colombia | 1 | <1% |
| Chile | 1 | <1% |
| Brazil | 1 | <1% |
| South Africa | 1 | <1% |
| Sri Lanka | 1 | <1% |
| Unknown | 273 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 39 | 14% |
| Researcher | 33 | 12% |
| Student > Bachelor | 27 | 10% |
| Student > Ph. D. Student | 27 | 10% |
| Student > Doctoral Student | 19 | 7% |
| Other | 45 | 16% |
| Unknown | 90 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 97 | 35% |
| Nursing and Health Professions | 27 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 4% |
| Psychology | 7 | 3% |
| Agricultural and Biological Sciences | 6 | 2% |
| Other | 35 | 13% |
| Unknown | 98 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2023.
All research outputs
#6,607,520
of 25,711,518 outputs
Outputs from Cochrane database of systematic reviews
#8,229
of 13,134 outputs
Outputs of similar age
#52,168
of 207,949 outputs
Outputs of similar age from Cochrane database of systematic reviews
#178
of 285 outputs
Altmetric has tracked 25,711,518 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 13,134 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.7. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,949 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 285 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.